Skip to content
MedsAcross

Medicine

Gobarden 100 mg/4 mL injection

Bendamustine · Intravenous · Avyxa Pharma
Available on requestPrescription onlyUS FDA Cold chain

Gobarden 100 mg/4 mL injection is a prescription medicine containing Bendamustine for intravenous use, marketed by Avyxa Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Cold chain

Store GOBARDEN in refrigerator, 2°C to 8°C (36°F to 46°F). Retain in original…

Key facts

Active ingredient (INN)
Bendamustine
Brand
Gobarden
Strength
100 mg/4 mL
Dosage form
Injection
Route
Intravenous
Packs
1 vial of 4 mL
Marketing authorisation holder
Avyxa Pharma
Manufacturer
Avyxa Pharma
Origin register
US FDA, United States
Storage
Store GOBARDEN in refrigerator, 2°C to 8°C (36°F to 46°F). Retain in original carton until time of use to protect from light.
Cold chain
Yes, shipped temperature controlled
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
L01AA09 Bendamustine
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
25 September 2026
Identifiers
RxCUI 1726097, 2754334DailyMed set ID 353fdf70-2720-41d3-a6fc-7baf0d793282NDC 83831-176Application NDA219014

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
1 vial in 1 carton / 4 mL in 1 vial83831-176-04AVYXA Pharma25 September 2026

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 20 March 2008Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Bendamustine 100 mg/4 mL injection.

Compare all 4

Other strengths and forms of Bendamustine

Clinical summary

Bendamustine is an alkylating drug indicated for treatment of patients with chronic lymphocytic leukemia (CLL), among other approved uses. It is available as powder for injection and injection for intravenous use. MedsAcross supplies Bendamustine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Bendamustine

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Gobarden 100 mg/4 mL injection for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.